ESRD due to multiple myeloma in the United States, 2001-2010

Journal of the American Society of Nephrology

Volumn 27, Issue 5, 2016, Pages 1487-1494

  Reule, Scott ^a,b   Sexton, Donal J ^a,b   Solid, Craig A ^b   Chen, Shu Cheng ^b   Foley, Robert N ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; END STAGE RENAL DISEASE; ETHNIC DIFFERENCE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MORTALITY RATE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX RATIO; SURVIVAL RATE; TREND STUDY; UNITED STATES; COMPLICATION; KIDNEY FAILURE, CHRONIC; TIME FACTOR;

ADULT; AGED; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84992445912     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014090876     Document Type: Article

References (31)

1. Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J, Schmaldienst S, Dekker F, Verrina E, Jager KJ: Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERAEDTA Registry study. Nephrol Dial Transplant 25: 1200-1206, 2010
2. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011
3. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, VekemansMC, Voillat L,MichalletM, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1782-1791, 2012
4. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Bladé J: Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J ClinOncol 26: 2171-2177, 2008
5. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679-686, 2010
6. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R; InterGroupe Francophone du Myélome: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-2502, 2003
7. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P; Group Myelome-Autogreffe: Highdose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-termresults of a randomized control trial fromthe Group Myelome-Autogreffe. J Clin Oncol 23: 9227-9233, 2005
8. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH,Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR; Eastern Cooperative Oncology Group: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11: 29-37, 2010
9. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, DrakeMT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic: Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 88: 360-376, 2013
10. ChngWJ, Dispenzieri A, ChimCS, Fonseca R,Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group: IMWG consensus on risk stratification in multiple myeloma. Leukemia 28: 269-277, 2014
11. Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F,Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R,Montefusco V, Falcone AP,Omedé P,Marasca R,Morabito F,Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32: 634-640, 2014
12. Korbet SM, Schwartz MM: Multiple myeloma. J Am Soc Nephrol 17: 2533-2545, 2006
13. Abbott KC, Agodoa LY: Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 56: 207-210, 2001
14. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, HuffmanMD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, ReevesMJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131: e29-e322, 2015
15. Kumar SK, Rajkumar SV, Dispenzieri A, LacyMQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111: 2516-2520, 2008
16. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999
17. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, CeccarelliM,AmbrosiniMT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network, GIMEMA: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367: 825-831, 2006
18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, AlsinaM, Alexanian R, Siegel D,Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003
19. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106: 4050-4053, 2005
20. Bringhen S, Petrucci MT, Larocca A, Conticello C, Rossi D, Magarotto V,Musto P, Boccadifuoco L,OffidaniM,Omedé P,Gentilini F, Ciccone G, Benevolo G, Genuardi M, Montefusco V, Oliva S, Caravita T, Tacchetti P, Boccadoro M, Sonneveld P, Palumbo A: Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood 124: 63-69, 2014
21. Kristinsson SY, AndersonWF, LandgrenO: Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 28: 1346-1348, 2014
22. Pozzi S, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, QuaresimaM,Cirilli C, Ferri P, FedericoM, Sacchi S: Survival ofmultiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol 163: 40-46, 2013
23. Turesson I, Velez R, Kristinsson SY, Landgren O: Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28: 830-834, 2010
24. Waxman AJ,Mink PJ, Devesa SS, AndersonWF,Weiss BM, Kristinsson SY, McGlynn KA, Landgren O: Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116: 5501-5506, 2010
25. Rhee CM, Lertdumrongluk P, Streja E, Park J, Moradi H, LauWL, Norris KC, Nissenson AR, Amin AN, Kovesdy CP, Kalantar-Zadeh K: Impact of age, race and ethnicity on dialysis patient survival and kidney transplantation disparities. Am J Nephrol 39: 183-194, 2014
26. StatBite: StatBite: Multiple myeloma and African Americans: higher incidence but fewer autologous stemcell transplants.JNatl Cancer Inst 101: 1610, 2009
27. Rohatgi N, Du XL, Coker AL,Moye LA,WangM, Fang S: Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort. Am J Clin Oncol 30: 540-548, 2007
28. Greenberg AJ, Philip S, Paner A, Velinova S, Badros A, Catchatourian R, Ketterling R, Kyle RA, Kumar S, Vachon CM, Rajkumar SV: Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J 5: e279, 2015
29. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV: Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119: 2100-2105, 2012
30. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program, 2014. Available at: http://seer.cancer.gov/data/citation.html. Accessed May 7, 2015
31. Howell DA, Wang HI, Roman E, Smith AG, Patmore R, Johnson MJ, Garry AC, Howard MR: Variations in specialist palliative care referrals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myeloma. BMJ Support Palliat Care 0: 1-7, 2014